SCSisi Chen

Sisi Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sisi Chen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The effect of COVID-19 on patients with liver cirrhosis: A systematic review and meta-analysis of retrospective studies (Preprint)

    by Qiaoxin Wei, Sisi Chen, Linlin Wei, Xiangying Zhang, Mei Liu, Feng Ren

    BACKGROUND Coronavirus disease 2019 (COVID-19) is long-lasting and has an adverse effect on liver function. However, the impact of COVID-19 on the outcome of patients with liver cirrhosis has not been consistently clear. OBJECTIVE We aimed to conduct a systematic review and meta-analysis to explore whether COVID-19 negatively impacts cirrhosis patients. METHODS We conducted a systematic search of the PubMed/Medline, Embase, and Cochrane Library databases to compare cirrhosis patients with and without COVID-19. Two authors independently performed data extraction and quality evaluation using the Newcastle‒Ottawa Scale. Data pooling was conducted using random-effects or fixed-effects models based on the heterogeneity of the included studies. RESULTS A total of 13 studies were included that involved 949 patients with cirrhosis and COVID-19 and 15,196 patients with cirrhosis only. Of the 13 studies, ten were studies among hospitalized patients, and three were studies among discharged patients. COVID-19 infection increased the mortality, ICU (Intensive Care Unit) admission rate, length of hospital stay and incidence of acute-on-chronic liver failure (ACLF), Child‒Pugh C and hepatic encephalopathy among hospitalized patients with liver cirrhosis. However, COVID-19 infection did not affect the mortality rate or the incidence of Child‒Pugh C among patients with cirrhosis after discharge. CONCLUSIONS In hospitalized patients with cirrhosis, infection with COVID-19 may be a potential risk factor for adverse clinical outcomes. However, COVID-19 infection seems to have no effect on patients with cirrhosis after discharge. It is recommended that clinicians pay more attention to the prevention and treatment of COVID-19 in patients with preexisting liver cirrhosis. CLINICALTRIAL PROSPERO CRD42023429256; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=429256

  • Open Access

    Performance of Hepatitis Delta Virus (HDV) RNA Testing for the Diagnosis of Active HDV Infection: Systematic Review and Meta-analysis

    by Sisi Chen, Xiangying Zhang, Ling Xu, Yuan Tian, Zihao Fan, Yaling Cao, Zhenzhen Pan, Yao Gao, Sujun Zheng, Zhongping Duan, et al.

    Hepatitis delta virus (HDV) is a defective virus and causes severe liver disease. Several HDV RNA assays have been developed, however the diagnostic efficacy remains unclear.This systematic review and meta-analysis aims to evaluate the diagnostic accuracy of HDV RNA assays to aid in the diagnosis of active hepatitis D.


  • Open Access

    Underestimated Prevalence of HIV, Hepatitis B Virus (HBV), and Hepatitis D Virus (HDV) Triple Infection Globally: Systematic Review and Meta-analysis

    by Sisi Chen, Feng Ren, Xiaojie Huang, Ling Xu, Yao Gao, Xiangying Zhang, Yaling Cao, Zihao Fan, Yuan Tian, Mei Liu

    Background: Hepatitis delta virus (HDV) is a satellite RNA virus that relies on hepatitis B virus (HBV) for transmission. HIV/HBV/HDV coinfection or triple infection is common and has a worse prognosis than monoinfection. Objective: We aimed to reveal the epidemiological characteristics of HIV/HBV/HDV triple infection in the global population. Methods: A systematic literature search in PubMed, Embase, and the Cochrane Library was performed for studies of the prevalence of HIV/HBV/HDV triple infection published from January 1, 1990, to May 31, 2021. The Der Simonian-Laird random effects model was used to calculate the pooled prevalence. Results: We included 14 studies with 11,852 participants. The pooled triple infection rate in the global population was 7.4% (877/11,852; 95% CI 0.73%-29.59%). The results of the subgroup analysis showed that the prevalence of triple infection was significantly higher in the Asian population (214/986, 21.4%; 95% CI 7.1%-35.8%), in men (212/5579, 3.8%; 95% CI 2.5%-5.2%), and in men who have sex with men (216/2734, 7.9%; 95% CI 4.3%-11.4%). In addition, compared with people living with HIV, the HIV/HBV/HDV triple infection rate was higher in people with hepatitis B. Conclusions: This meta-analysis suggests that the prevalence of HIV/HBV/HDV triple infection in the global population is underestimated, and we should focus more effort on the prevention and control of HIV/HBV/HDV triple infection. Trial Registration: PROSPERO CRD42021273949; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=273949


  • Open Access

    Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure

    by Linlin Wei, Ting Wang, Sisi Chen, Yeying Liu, Xueying Huang, Sujun Zheng, Bin Xu, Feng Ren, Mei Liu

    Linlin Wei, Ting Wang, Sisi Chen, Yeying Liu, Xueying Huang, Sujun Zheng, Bin Xu, Feng Ren, and Mei Liu. Gut and Liver 2023;17:795-805. https://doi.org/10.5009/gnl220022